Italy
· Delayed Price · Currency is EUR Svas Biosana Statistics
Total Valuation
Svas Biosana has a market cap or net worth of EUR 41.98 million. The enterprise value is 70.57 million.
| Market Cap | 41.98M |
| Enterprise Value | 70.57M |
Important Dates
The last earnings date was Thursday, May 15, 2025.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | Jun 9, 2025 |
Share Statistics
Svas Biosana has 5.31 million shares outstanding.
| Current Share Class | 5.31M |
| Shares Outstanding | 5.31M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.45% |
| Owned by Institutions (%) | 10.14% |
| Float | 1.87M |
Valuation Ratios
The trailing PE ratio is 7.17 and the forward PE ratio is 6.08.
| PE Ratio | 7.17 |
| Forward PE | 6.08 |
| PS Ratio | 0.34 |
| PB Ratio | 0.67 |
| P/TBV Ratio | 0.82 |
| P/FCF Ratio | 29.47 |
| P/OCF Ratio | 8.16 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.83, with an EV/FCF ratio of 49.54.
| EV / Earnings | 12.01 |
| EV / Sales | 0.58 |
| EV / EBITDA | 4.83 |
| EV / EBIT | 7.20 |
| EV / FCF | 49.54 |
Financial Position
The company has a current ratio of 1.98, with a Debt / Equity ratio of 1.05.
| Current Ratio | 1.98 |
| Quick Ratio | 1.42 |
| Debt / Equity | 1.05 |
| Debt / EBITDA | 4.51 |
| Debt / FCF | 46.31 |
| Interest Coverage | 2.25 |
Financial Efficiency
Return on equity (ROE) is 9.65% and return on invested capital (ROIC) is 4.81%.
| Return on Equity (ROE) | 9.65% |
| Return on Assets (ROA) | 3.70% |
| Return on Invested Capital (ROIC) | 4.81% |
| Return on Capital Employed (ROCE) | 9.50% |
| Revenue Per Employee | 373,966 |
| Profits Per Employee | 17,966 |
| Employee Count | 327 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 2.64 |
Taxes
In the past 12 months, Svas Biosana has paid 2.13 million in taxes.
| Income Tax | 2.13M |
| Effective Tax Rate | 26.63% |
Stock Price Statistics
The stock price has increased by +4.81% in the last 52 weeks. The beta is 0.93, so Svas Biosana's price volatility has been similar to the market average.
| Beta (5Y) | 0.93 |
| 52-Week Price Change | +4.81% |
| 50-Day Moving Average | 7.60 |
| 200-Day Moving Average | 7.48 |
| Relative Strength Index (RSI) | 48.43 |
| Average Volume (20 Days) | 7,618 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Svas Biosana had revenue of EUR 122.29 million and earned 5.87 million in profits. Earnings per share was 1.10.
| Revenue | 122.29M |
| Gross Profit | 34.37M |
| Operating Income | 9.80M |
| Pretax Income | 8.01M |
| Net Income | 5.87M |
| EBITDA | 14.62M |
| EBIT | 9.80M |
| Earnings Per Share (EPS) | 1.10 |
Balance Sheet
The company has 37.39 million in cash and 65.97 million in debt, giving a net cash position of -28.58 million or -5.38 per share.
| Cash & Cash Equivalents | 37.39M |
| Total Debt | 65.97M |
| Net Cash | -28.58M |
| Net Cash Per Share | -5.38 |
| Equity (Book Value) | 62.84M |
| Book Value Per Share | 11.79 |
| Working Capital | 60.83M |
Cash Flow
In the last 12 months, operating cash flow was 5.14 million and capital expenditures -3.72 million, giving a free cash flow of 1.42 million.
| Operating Cash Flow | 5.14M |
| Capital Expenditures | -3.72M |
| Free Cash Flow | 1.42M |
| FCF Per Share | 0.27 |
Margins
Gross margin is 28.10%, with operating and profit margins of 8.02% and 4.80%.
| Gross Margin | 28.10% |
| Operating Margin | 8.02% |
| Pretax Margin | 6.55% |
| Profit Margin | 4.80% |
| EBITDA Margin | 11.96% |
| EBIT Margin | 8.02% |
| FCF Margin | 1.16% |
Dividends & Yields
This stock pays an annual dividend of 0.25, which amounts to a dividend yield of 3.16%.
| Dividend Per Share | 0.25 |
| Dividend Yield | 3.16% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 27.24% |
| Buyback Yield | n/a |
| Shareholder Yield | 3.11% |
| Earnings Yield | 14.00% |
| FCF Yield | 3.39% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Svas Biosana has an Altman Z-Score of 1.83 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.83 |
| Piotroski F-Score | 6 |